BioCentury
ARTICLE | Company News

3SBio acquires Zhejiang Wansheng

July 25, 2015 1:12 AM UTC

3SBio Inc. (HKSE:1530) will acquire Zhejiang Wansheng Pharmaceutical Co. Ltd. (Hangzhou, China) for RMB528 million ($85.1 million).

Zhejiang Wansheng markets oncology, diabetes and hypertension products. 3SBio said the acquisition would allow the company to expand into diabetes and dermatology markets. ...